Table 6.
Summary of TEAEs Affecting > 5% of Participants
| TEAEs | CVC 150 mg (n = 24), n (%) |
|---|---|
| TEAEs affecting > 5% of participants | |
| Fatigue | 4 (16.7) |
| Rash | 4 (16.7) |
| Dizziness | 4 (16.7) |
| Headache | 3 (12.5) |
| Cough | 3 (12.5) |
| Vomiting | 3 (12.5) |
| Pruritus | 2 (8.3) |
| Rash pruritic | 2 (8.3) |
| Nausea | 2 (8.3) |
| Pyrexia | 2 (8.3) |
| Arthralgia | 2 (8.3) |
| Musculoskeletal chest pain | 2 (8.3) |
| Lower respiratory tract infection | 2 (8.3) |
A TEAE is any adverse event that has an onset date and time on or after the date and time of first administration of study drug. Adverse events that worsen after administration of study medication are also categorized as TEAEs.